EDAP TMS S.A. (EDAP) At $3.36 Forms Bottom; First Light Asset Management Has Decreased Its Bluebird Bio (BLUE) Position

bluebird bio, Inc. (NASDAQ:BLUE) Logo

EDAP TMS S.A. (EDAP) formed multiple bottom with $3.23 target or 4.00% below today’s $3.36 share price. EDAP TMS S.A. (EDAP) has $97.43 million valuation. The stock increased 1.20% or $0.04 during the last trading session, reaching $3.36. About 530,512 shares traded. EDAP TMS S.A. (NASDAQ:EDAP) has declined 14.64% since June 14, 2017 and is downtrending. It has underperformed by 27.21% the S&P500. Some Historical EDAP News: ; 14/05/2018 – EDAP TMS 1Q EPS 0c; 21/03/2018 – EDAP SAYS CIGNA TO COVER HIFU FOR PROSTATE PROCEDURE; 03/04/2018 – EDAP TMS: Results Confirm HIFU’s Safety, Efficacy and Benefits for Patients’ Quality of Life; 21/03/2018 – EDAP TMS SA : EDAP Announces CIGNA as First Major U.S. Private Health Insurer to Cover HIFU for Prostate Procedure; 27/03/2018 – EDAP TMS 4Q Rev $12.6M; 01/04/2018 – Edap TMS SA Conference Set By H.C. Wainwright for Apr. 8-10; 03/04/2018 – EDAP TMS SA : EDAP Reports First US Cohort Study Results of Focal HIFU Prostate Ablation Shows Promising Outcomes; 14/05/2018 – EDAP TMS 1Q Rev $11.3M; 27/03/2018 – EDAP TMS SA : EDAP Reports 2017 Annual Results; 14/03/2018 EDAP TMS SA : EDAP TMS to Announce Year End 2017 Financial Results on Tuesday, March 27, 2018

First Light Asset Management Llc decreased Bluebird Bio Inc (BLUE) stake by 32.83% reported in 2018Q1 SEC filing. First Light Asset Management Llc sold 12,422 shares as Bluebird Bio Inc (BLUE)’s stock declined 6.46%. The First Light Asset Management Llc holds 25,416 shares with $4.34 million value, down from 37,838 last quarter. Bluebird Bio Inc now has $9.43 billion valuation. The stock increased 1.81% or $3.35 during the last trading session, reaching $188.1. About 557,798 shares traded. bluebird bio, Inc. (NASDAQ:BLUE) has risen 135.78% since June 14, 2017 and is uptrending. It has outperformed by 123.21% the S&P500. Some Historical BLUE News: ; 01/05/2018 – Kymriah(R) (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma; 28/03/2018 – bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States; 09/03/2018 CAR-T Cell Therapy for Liver and Lung Cancer – Pipeline Analysisl Technavio; 02/05/2018 – Humanigen Announces Preclinical Findings Presented on Lenzilumab’s Potential to Optimize CAR-T Therapy; 16/04/2018 – Humanigen Signs Agreement With MD Anderson Cancer Center to Begin Research Investigating Lenzilumab as CAR-T Support; 01/05/2018 – Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r; 28/03/2018 – BLUEBIRD BIO INC – BLUEBIRD AND CELGENE WILL SHARE 50% OF U.S. COSTS AND PROFITS; 28/03/2018 – BLUEBIRD BIO-CELGENE TO CO-DEVELOP ANTI-BCMA CAR T CELL THERAPY; 21/03/2018 – BLUEBIRD BIO INC BLUE.O : MORGAN STANLEY RAISES TARGET PRICE TO $209 FROM $152; 31/05/2018 – bluebird bio Coverage Assumed by PiperJaffray at Overweight

Analysts await EDAP TMS S.A. (NASDAQ:EDAP) to report earnings on August, 22. They expect $-0.02 EPS, up 60.00% or $0.03 from last year’s $-0.05 per share. After $0.03 actual EPS reported by EDAP TMS S.A. for the previous quarter, Wall Street now forecasts -166.67% negative EPS growth.

More notable recent bluebird bio, Inc. (NASDAQ:BLUE) news were published by: Seekingalpha.com which released: “bluebird bio: Gene Therapy Best In Class” on May 16, 2018, also Nasdaq.com with their article: “3 Reasons Amazing Isn’t Good Enough for This Biotech Stock” published on June 05, 2018, Fool.com published: “Better Buy: Bellicum Pharmaceuticals, Inc. vs. bluebird bio” on May 24, 2018. More interesting news about bluebird bio, Inc. (NASDAQ:BLUE) were released by: Nasdaq.com and their article: “ASCO Conference Preview: Here’s What Biotech Investors Need to Watch” published on May 31, 2018 as well as Fool.com‘s news article titled: “Something Borrowed, Something Blue, Volume 2: It’s Been a Roller-Coaster Ride for BLUE Shareholders” with publication date: May 30, 2018.

Among 28 analysts covering bluebird bio (NASDAQ:BLUE), 16 have Buy rating, 2 Sell and 10 Hold. Therefore 57% are positive. bluebird bio had 101 analyst reports since August 11, 2015 according to SRatingsIntel. As per Wednesday, February 3, the company rating was initiated by Leerink Swann. The stock of bluebird bio, Inc. (NASDAQ:BLUE) earned “Outperform” rating by Oppenheimer on Tuesday, October 20. The stock has “Buy” rating by Leerink Swann on Wednesday, November 1. The stock of bluebird bio, Inc. (NASDAQ:BLUE) earned “Hold” rating by Oppenheimer on Wednesday, March 28. The firm has “Buy” rating given on Monday, March 5 by William Blair. Morgan Stanley maintained bluebird bio, Inc. (NASDAQ:BLUE) on Wednesday, June 14 with “Hold” rating. As per Monday, February 6, the company rating was downgraded by TH Capital. The stock of bluebird bio, Inc. (NASDAQ:BLUE) has “Equal-Weight” rating given on Wednesday, March 21 by Morgan Stanley. The rating was maintained by BMO Capital Markets on Thursday, February 22 with “Outperform”. The firm earned “Hold” rating on Friday, June 3 by Cantor Fitzgerald.

Analysts await bluebird bio, Inc. (NASDAQ:BLUE) to report earnings on August, 1. They expect $-2.34 EPS, down 35.26% or $0.61 from last year’s $-1.73 per share. After $-2.31 actual EPS reported by bluebird bio, Inc. for the previous quarter, Wall Street now forecasts 1.30% negative EPS growth.

bluebird bio, Inc. (NASDAQ:BLUE) Ratings Chart